Zeke Capital Advisors’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Zeke Capital Advisors’s Portfolio MTACU Stock Details MTACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$2.01M	–	534
2021 Q4	$2.01M	Hold	200,000	–	–	0.12%	62
2021 Q3	$2.03M	Hold	200,000	–	–	0.12%	64
2021 Q2	$2M	Hold	200,000	–	–	0.13%	70
2021 Q1	$2.01M	Buy	+200,000	New	+$2.13M	0.14%	61

Other funds holding MTACU

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

ICMH

Integrity Capital Management (HK) Central, Hong Kong $64K AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Zeke Capital Advisors's MTACU Position: Q1 2022 in Review

Zeke Capital Advisors sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2022, closing a stake of 200,000 shares — an estimated $2.01M sold.

Zeke Capital Advisors first reported a position in MTACU in Q1 2021 and held it in 4 quarters. The position peaked at $2.03M in Q3 2021. 5 funds tracked by Wall St. Rank hold MTACU as of Q1 2022.

Zeke Capital Advisors reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2022 after selling out during the quarter.
Zeke Capital Advisors sold 200,000 MedTech Acquisition Corporation Unit shares in Q1 2022, an estimated $2.01M.
Zeke Capital Advisors first reported a position in MedTech Acquisition Corporation Unit in Q1 2021 and held it in 4 quarters.
Zeke Capital Advisors's MedTech Acquisition Corporation Unit position peaked at $2.03M in Q3 2021.
5 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2022.

Based on Zeke Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.